Characterization of the C-Terminal Region of CMPD, a putative cytoplasmic protein

Target Name: LINC01152

NCBI ID: G102606463

LINC01152

Other Name(s): CMPD | TCONS_00025128 | Long intergenic non-protein coding RNA 1152, transcript variant 1 | long intergenic non-protein coding RNA 1152

Characterization of the C-Terminal Region of CMPD, a putative cytoplasmic protein

LINC01152 (C-terminal region), also known as CMPD (conditioned medium-reported protein), is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the CMP family, which includes proteins that play a critical role in the regulation of cellular processes, including cell signaling, DNA replication, and protein synthesis.

CMPD is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is characterized by a N-terminal domain that contains a putative transmembrane segment and a C-terminal region that contains a series of conserved hypothetical cytoplasmic domains. The C-terminal region of CMPD is unique among its CMP family members, as it contains a unique domain that is not found in any other member of the family.

The C-terminal region of CMPD contains a series of conserved hypothetical cytoplasmic domains that are involved in the regulation of cellular processes. These domains include a calcineurin-like domain, a Ku70-like domain, a scaffold domain, and a basic domain. The calcineurin-like domain is involved in the regulation of protein synthesis and is characterized by the presence of a nucleotide-binding oligomerization domain (NBO domain) and acalineurin-like domain. The Ku70-like domain is involved in the regulation of DNA replication and is characterized by the presence of a nucleotide-binding oligomerization domain (NBO domain). The scaffold domain is involved in the regulation of protein structure and is characterized by the presence of a nucleotide-binding oligomerization domain (NBO domain) and a alpha-helices domain. The basic domain is involved in the regulation of protein function and is characterized by the presence of a nucleotide-binding oligomerization domain (NBO domain).

CMPD is involved in a number of cellular processes, including the regulation of protein synthesis, DNA replication, and cell signaling. For example, CMPD has been shown to play a role in the regulation of protein synthesis in the brain, where it is involved in the regulation of the translation of pre-mRNA to protein. Additionally, CMPD has been shown to play a role in the regulation of DNA replication in the heart, where it is involved in the regulation of the DNA replication machinery.

CMPD is also involved in the regulation of cell signaling. For example, CMPD has been shown to play a role in the regulation of neurotransmitter release in the brain, where it is involved in the regulation of the release of neurotransmitters such as dopamine and GABA. Additionally, CMPD has been shown to play a role in the regulation of cell adhesion, where it is involved in the regulation of the formation of tight junctions in the brain.

In conclusion, CMPD is a unique and conserved protein that is involved in a number of critical cellular processes. Its C-terminal region contains a series of hypothetical cytoplasmic domains that are involved in the regulation of protein synthesis, DNA replication, and cell signaling. As such, CMPD is a potential drug target and may be useful for the development of new treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1152

The "LINC01152 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01152 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets